Inhaled interferon could be new weapon against severe RSV in young children

This phase 3 trial tests whether an inhaled solution of human interferon α1b can safely help children under 2 years old recover from respiratory syncytial virus (RSV) lower respiratory tract infections. The study compares the interferon treatment to a placebo, measuring improvements in breathing difficulty and other symptoms. Around 322 children will participate to see if this approach speeds up recovery and reduces illness severity.